A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds by Cohn-Hokke, P.E. (P.) et al.
RESEARCH ARTICLENeuropsychiatric GeneticsA Novel CCM2 Variant in a Family With
Non-Progressive Cognitive Complaints and
Cerebral Microbleeds
Petra E. Cohn-Hokke,1* Henne Holstege,1,2 Marjan M. Weiss,1 Wiesje M. van der Flier,2,3
Frederik Barkhof,4 Erik A. Sistermans,1 Yolande A. L. Pijnenburg,2 John C. van Swieten,1,2,5
Hanne Meijers-Heijboer,1 and Philip Scheltens2
1Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands
2Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands
3Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands
4Department of Radiology & Nuclear Medicine, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam,
The Netherlands
5Department of Neurology, Erasmus Medical Center, Rotterdam, The NetherlandsManuscript Received: 25 February 2016; Manuscript Accepted: 25 May 2016This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution
and reproduction in any medium, provided the original work is properly
cited and is not used for commercial purposes.
Conflicts of interest: The authors declare no conflicts of interest.
Grant sponsor: Alzheimer Nederland; Grant sponsor: Stichting VUmc
fonds.
Correspondence to:
Petra E. Cohn-Hokke,M.D., Department of Clinical Genetics, VUUniversity
Medical Center, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands.
E-mail: p.cohn@vumc.nl
Article first published online in Wiley Online Library
(wileyonlinelibrary.com): 8 June 2016
DOI 10.1002/ajmg.b.32468
How to Cite this Article:
Cohn-Hokke PE, Holstege H, Weiss MM,
van der Flier WM, Barkhof F, Sistermans
EA, Pijnenburg YAL, van Swieten JC,
Meijers-Heijboer H, Scheltens P. 2017.
A Novel CCM2 Variant in a Family With
Non-Progressive Cognitive Complaints and
Cerebral Microbleeds.
Am J Med Genet Part B 174B:220–226.Lobar cerebral microbleeds are most often sporadic and associ-
ated with Alzheimer’s disease. The aim of our study was to
identify the underlying genetic defect in a family with cognitive
complaints andmultiple lobarmicrobleeds and a positive family
history for early onset Alzheimer’s disease. We performed
exome sequencing followed by Sanger sequencing for validation
purposes on genomic DNA of three siblings with cognitive
complaints, reduced amyloid-beta-42 in CSF and multiple cere-
bral lobar microbleeds. We checked for the occurrence of the
variant in a cohort of 363 patientswith early onset dementia and/
or microbleeds. A novel frameshift variant (c.236_237delAC)
generating a premature stop codon in the CCM2 gene shared by
all three siblings was identified. Pathogenicity of the variant was
supported by the presence of cerebral cavernous malformations
in two of the siblings and by the absence of the variant exome
variant databases. Two siblings were homozygous for APOE-e4;
one heterozygous. The cognitive complaints, reduced amyloid-
beta-42 in CSF and microbleeds suggest preclinical Alzheimer’s
disease, but the stability of the cognitive complaints does not.
We hypothesize that the phenotype in this familymay be due to a
combination of the CCM2 variant and the APOE status.
 2016 The Authors. American Journal of Medical Genetics Part B: Neuro-
psychiatric Genetics Published by Wiley Periodicals, Inc.
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cognitive impairment; familial clustering; genetics
INTRODUCTION
Cerebral microbleeds (CMBs), small round hypointense lesions on
hemosiderin sensitive MR sequences, are common in Alzheimer’s
disease patients but also occur in the general population [Cordon-
nier and van der Flier, 2011; Shams et al., 2015]. Based on clinical2016 The Authors. American Journal of Medical Genetics Part B: Nand epidemiological studies, CMBs with a lobar location presum-
ably represent cerebral amyloid angiopathy (CAA), while CMBs
with a deep location may represent hypertensive vasculopathy
[Cordonnier et al., 2006; Poels et al., 2010; Shams et al., 2015].
CAA ismost often sporadic, with age being themost important risk
factor [Biffi and Greenberg, 2011]. Specific (founder) mutations in
the amyloid-precursor protein (APP) gene, the cystatin 3 (CST3)europsychiatric Genetics Published by Wiley Periodicals, Inc. 220
COHN-HOKKE ET AL. 221gene, and the intergral membrane protein 2B (ITM2B) gene are
associated with hereditary CAA [Ghiso et al., 1986; Vidal et al.,
1999, 2000]. Mutations in presenilin 1 (PSEN1) and presenilin 2
(PSEN2) genes are associated with familial early onset Alzheimer’s
disease with CAA [Nochlin et al., 1998; Dermaut et al., 2001;
Sanchez-Valle et al., 2007]. The APOE e4 allele is the strongest
known genetic risk factor for Alzheimer’s disease [van der Flier
et al., 2006; Kanekiyo et al., 2014], but is also associated with the
incidence and severity of CAA [Esiri et al., 2015] and with the
prevalence of CMBs in Alzheimer’s disease patients [Benedictus
et al., 2013; Yates et al., 2014].
We present a family with CMBs and cognitive complaints with
no known genetic predisposition for CAA or Alzheimer’s disease,
in whom we performed whole exome sequencing in three affected
siblings. We detected a deletion leading to a frameshift in the
CCM2 gene, a gene associated with familial cerebral cavernous
malformations.MATERIALS AND METHODS
Clinical Ascertainment
We selected a family of which two family members were known at
our clinic, the Alzheimer center of the VU University Medical
Center, because of cognitive complaints and microbleeds and an
autosomal dominant family history for Alzheimer’s disease.
All patients visiting the Alzheimer center are offered an extensive
standardized dementia assessment includingmedical history, infor-
mant-based history, a physical examination, routine blood (includ-
ing glucose) and cerebrospinal fluid (CSF) laboratory tests,
neuropsychological testing, electroencephalogram (EEG), andmag-
netic resonance imaging (MRI)of the brain including susceptibility-
weighted T2 images [van der Flier et al., 2014]. The clinical
diagnosis Alzheimer’s disease is made by consensus in a multidisci-
plinary teambasedon theNINCDS-ADRDAcriteria forAlzheimer’s
disease [McKhann et al., 1984], and a clinical diagnosis mild
cognitive impairment (MCI) based on the Petersen criteria
[Petersen,2004].Patientsare labeledashaving subjectivecomplaints
when reporting cognitive complaintswhile cognitive and laboratory
investigations are normal and criteria for MCI, dementia or any
other neurological or psychiatric disorder associated with cognitive
complaints are not met. All patients who give consent for research
are included in theAmsterdamDementiaCohort [vanderFlier et al.,
2014]. A subset of this cohort, consisting of 363 patients with early
onset AD and/or multiple microbleeds, was selected for whole
exome sequencing for other research purposes.
All participants of this study had at least two MRI’s performed
on a 3.0 T GE scanner (type HDXT) with SWI sequence. Analysis
of small vessel disease was performed according to STRIVE
[Wardlaw et al., 2013]. The three participating subjects of the
described family gave written informed consent for genetic re-
search specifically prior to inclusion. The research protocol was
approved by the ethical review board of our hospital.
Genetic Analysis
DNA of the described participants and of the 363 selected patients
of the Amsterdam dementia cohort was derived from peripheralblood. Exomes were captured by the Nimblegen human exome v3
capture kit, and were sequenced with 2 100 paired-end sequenc-
ing on the Illumina HiSeq 2000 platform, according to the man-
ufacturer’s protocol. Reads were mapped to the human reference
genome sequence (UCSC hg19) using the Burrows-Wheeler Align-
ment Tool (http://bio-bwa.sourceforge.net) [Li andDurbin, 2009].
Duplicate read removal, local sequence realignment, and base
quality recalibration were performed by Picard (http://picard.
sourceforge.net) and Genome analysis Tool Kit (GATK, (https://
www.broadinstitute.org/gatk/) [McKenna et al., 2010]. Variants
were called using the GATKHaplotypeCaller, and filtered using the
variant filtration tool. For each variant, we set the filter to PASS if
the variant complied with (i) GATK quality score50; (ii) quality
over depth 1.5; (iii) Strand bias 60; (iv) total read depth 5.0.
Variants were annotated and analyzed with Cartagenia (http://
www.cartagenia.com/) filter tree specifically designed to detect
variants causative for a trait with an autosomal dominant inheri-
tance pattern. In the described family, variants were selected if
(i) absent in the following databases: dbSNP (http://www.ncbi.
nlm.nih.gov/projects/SNP, build 138), the 1.000 genome project
(www.1000genomes.org) or the National Heart Lung Blood Insti-
tute Exome Variant Server (EVS) (https://evs.gs.washing ton.edu/
EVS); (ii) prevalent 5% in the 363 patients of the Amsterdam
Dementia Cohort [van der Flier et al., 2014]; (iii) heterozygote in
all three affected individuals; (iv) potential causative based on
the possible effects of the variants on the expression or function of
the protein and in a morbid OMIM gene.
To find out whether a predisposition for CCMs is common in
patients with presumed microbleeds, we searched the exomes
of 363 patients of the Amsterdam Dementia Cohort [van der
Flier et al., 2014], including 68 patients with microbleeds,
for occurrence of exonic and splice site variants in the genes
KRIT1, CCM2, and PDCD10. Nucleotides were numbered
according to Genbank accession number NM_004912.3 (KRIT1),
NM_001029835.2 (CCM2), and NM_007217.3 (PDCD10) with A
of initiator ATG numbered as þ1. Variants in the CCM genes
were analyzed by using the Combined Annotation Dependent
Deletion (CADD) scoring tool (http://cadd.gs.washington.edu/)
v1.2.We used Sanger sequencing to confirm the novel variant we
found with exome sequencing. We submitted the variant in the
CCM2 gene to the Leiden Open Variant Database (http://ccm2.
lovd.nl).
APOE genotyping was performed by Sanger sequencing of
codons 112 and 158 of the APOE gene. For this, a 428 bp fragment
was generated from genomic DNA by PCR, checked for size (Fast
DNA analysis with QIAxcel), and sequenced (BigDye Terminator
v3.1 Cycle Sequencing kit followed by ABI 3130XL Genetic
Analyzer).
RESULTS
Characteristics of the Participants
The pedigree is shown in Figure 1. Individuals III-1, III-2, and III-3
participated in our study. They reported early-onset dementia in
one parent (II-6) and one grandparent (I-1). Three siblings of
the affected parent had symptoms of dementia before the age of
65 years (II-1, II-2, and II-3), another relative (II-4) died of a stroke
FIG. 1. Pedigree of the described family. The sex of each
individual is masked and the pedigree scrambled to protect the
privacy of the participants. The diamonds indicate individuals
with cognitive complaints and microbleeds (filled symbols),
dementia (filled upper right quadrant), and stroke (filled lower
right quadrant). CCMþ indicates that the subject is positive for
the c.236_237delAC variant in the CCM2 gene. E3 indicates an
APOE e3 allele, E4 an APOE e4 allele. “n” in a diamond indicates
more than one individual. Consequently, the ID under the
symbols with an “n” refers to multiple individuals as a group.
222 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bof unknown aetiology. Of these reported affected relatives, neither
detailed medical information nor DNA was available.Case III-1
This patient visited our center at the age of 58 years with memory
complaints for over 5 years. The MMSE score was 27 out of 30.FIG. 2. Cerebral MR imaging. A: Microbleed (arrow) in individual III-1 visib
(arrow) in individual III-2 on T2-weighted image. C: Left frontal cavernous
high signal on T2 weighted image and hypointense outer rim.Physical examination, routine blood tests, neuropsychological
testing, and EEG were all normal. Cerebral MRI showed nine lobar
CMBs in the absence of cortical atrophy (global cortical atrophy
[GCA] score 0) and hippocampal atrophy (medial temporal lobe
atrophy [MTA] score 0) (Fig. 2A), a few punctiform white matter
lesions (Fazekas 1) and a large T2-hypointensity in the pons
consistent with a macroscopic hemorrhage. CSF analysis showed
decreased amyloid-beta-42 and increased tau levels (Ab: 529 ng/L,
reference> 550 ng/L; t-tau: 673 ng/L, reference 375 ng/L; ptau-
181: 86 ng/L, reference 52 ng/L). The patient was homozygous
for the APOE e4 allele. Diagnostic DNA-analysis revealed no
mutations in the genes APP (Sanger sequencing and copy number
variant analysis), PSEN1, PSEN2, and MAPT.
Since the clinical and neuropsychological exam were within
the normal range, the cognitive complaints were labeled as subjec-
tive cognitive decline. CMBs were interpreted as suggestive of
underlying CAA and the CSF biomarkers indicative of preclinical
AD.
During the following 7 years, the patient reported only mild
progression of her cognitive dysfunction, and neuropsychological
testing remained normal. Repeat MR imaging showed a few new
CMBs but still no signs suggestive of neurodegeneration such as
cortical atrophy.Case III-2
This patient visited our center at the age of 54 years with complaints
of long lastingmildmemory loss. Physical examination and routine
blood tests showed no relevant abnormalities. The patient scored
29 out of 30 on theMMSE, and neuropsychological testing revealed
only mild language disturbances. T2-weighted MR imaging
revealed three lobar CMBs, two larger hematomas (cerebellar
and parietal) with a hyperintense center on FLAIR and T1 consis-
tent with a cavernous malformation (Fig. 2B), and a few puncti-
form vascular white matter lesions (Fazekas 1); cerebral cortical orle on T2-weighted image. B: Left cerebellar cavernous malformation
malformation (arrow) in individual III-3 with characteristic central
COHN-HOKKE ET AL. 223hippocampal atrophy was absent (GCA 0, MTA 0). The EEG was
normal. CSF analysis showed decreased amyloid-beta-42 but nor-
mal t-tau and borderline p-tau levels (Ab: 418 ng/L, t-tau: 343 ng/L,
ptau-181: 56 ng/L). The patient was homozygous for the APOE e4
allele. No mutations were identified in the genes PSEN1, PSEN2,
and MAPT. The cognitive complaints were labelled as subjective
cognitive decline. The CMBs were interpreted as suggestive for
underlying CAA.
During the following 7 years, the patient reported a slight
worsening of cognitive complaints, which could not be confirmed
by neuropsychological testing (criteria for MCI not fulfilled).
Repeat MRI showedmild increase of white matter hyperintensities
and a few new lobar CMBs.Case III-3
The youngest sibling presented with progressive memory loss and
executive dysfunction at another hospital at the age of 51 years and
was diagnosed with Alzheimer’s disease. Detailed information on
the test results was not available. No mutations, duplications, or
deletions were found in the genes APP and PSEN1.
The patient visited our clinic for a second opinion 4 years later,
as symptoms had not worsened. At this time, MMSE was 25/30,
and neuropsychological assessment revealed executive dysfunc-
tion and mild impairment of memory and naming. MRI showed
more than 20 supra- and infratentorial lobar CMBs, a few
punctiform vascular white matter lesions (Fazekas 1), and a
cavernous malformation in the left frontal lobe (Fig. 2C). There
was no cortical atrophy (GCA 0) or relevant hippocampal atrophy
(MTA 0 on the left and grade 1 on the right). The patient had an
APOE e3/e4 genotype. A lumbar puncture was refused by the
participant.
The patient did not fulfill the criteria for Alzheimer’s disease
and was diagnosed with MCI. The CMBs were interpreted as
probably due to CAA. Two-year follow up showed no further
clinical deterioration.Genetic Findings
With exome sequencing, we identified a heterozygous two-base
pair deletion in exon 3, c.236_237delAC, in the CCM2 gene in all
three siblings. This deletion creates a frameshift starting at codon
Tyr79 resulting in a premature stop codon. Based on the location of
the new stop, the transcript is likely to be targeted by nonsense-
mediated mRNA decay, resulting in haploinsufficiency. The vari-
ant has not been reported before in literature or in the Dutch
genetic biobank GoNL (http://www.nlgenome.nl/) and was not
found in 363 patients with early onset Alzheimer’s disease and/or
multiple microbleeds. Based on the predicted effect of variants and
known function of the associated genes, we found no other variants
of interest in the family.
To investigate whether mutations in the CCM2-gene or related
genes are common in patients with CMBs, we analyzed the
cohort of 363 patients with early onset Alzheimers disease
and/or microbleeds for rare variants in the genes KRIT1,
CCM2, and PDCD10. We detected two missense variants of
unknown significance in the KRIT1 gene with a minor allelefrequency of less than 0.5%: One protein modifying variant,
c.1882A>C, p.Asn628His was found in an Alzheimer’s disease
patient without vascular abnormalities on brain imaging. This
variant has a CADD score of 23.1 and is found in the Dutch
genomic biobank GoNL with an allele frequency of 0.1%. A
synonymous variant, c.1752C>T, p.Ile584¼with a CADD score
of 17.5 was found in an Alzheimer’s disease patient with moder-
ately severe vascular white matter lesions but no CMBs or
cavernous malformations. The GoNL biobank reports an
allele frequency of close to 0.5% of this variant.DISCUSSION
We describe a novel variant in the CCM2 gene identified by whole
exome sequencing in a family with non-progressive cognitive
symptoms in three siblings at relatively young age, with CCMs
in two and multiple lobar CMBs in all three on cerebral MRI.
In addition, decreased amyloid beta-42 levels in CSF were found in
both tested individuals. Mutations in the genes APP, PSEN1, and
PSEN2 were absent, and at least one APOE e4 allele was present in
all three.
The novel frameshift variant generates a premature stop
codon in the CCM2 gene, probably resulting in haploinsuffi-
ciency by nonsense mediated mRNA decay. Loss of function
mutations in the CCM2 gene and in the genes KRIT1 and
PDCD10 are associated with familial cerebral cavernous malfor-
mations (FCCM) [Laberge-le et al., 1999; Sahoo et al., 1999;
Liquori et al., 2003; Bergametti et al., 2005]. Cerebral cavernous
malformations (CCMs) are enlarged, thin walled capillaries in
the brain and spinal cord without fibrous support tissue. In
familial cases, a combination of a germ line mutation (first hit)
and a somatic mutation (second hit) in one of the FCCM genes
are associated with CCMs [Akers et al., 2009; Pagenstecher et al.,
2009]. The KRIT1-CCM2-PDCD10-complex is considered to
interact with the PI3 K/Akt signaling pathway associated with
metabolism, growth, proliferation, survival, transcription, and
protein synthesis mechanisms [Kar et al., 2015]. Most symptom-
atic FCCM patients present between the age of 10 and 40 years
with seizures, focal neurologic deficits, non-specific headaches,
or acute cerebral hemorrhage [Denier et al., 2006]. Up to 50%
of the patients with FCCM remain asymptomatic, although
most asymptomatic mutation carriers do have at least one
CCM on MRI [Denier et al., 2006].
The presence of CCMs in two of the three siblings (individual
III-1 and III-2) supports the diagnosis of FCCM in this family.
The absence of a CCM in the third individual does not contradict
this diagnosis, since FCCM is known to have an incomplete
penetrance. However, decreased CSF amyloid beta-42 has not
been reported in FCCM and cognitive complaints and CMBs
are not common symptoms of this disease [Denier et al., 2006].
The (subjective) cognitive decline may reflect a concomitant
preclinical Alzheimer disease. The abnormal amyloid beta levels in
CSF and the presence of APOE e4 in homozygous or heterozygous
state in all three affected siblings would support this. However, the
stable character of the cognitive complaints over 7 years does not.
Poor cognitive function has also been associated with APOE e4
status in the absence of Alzheimer’s disease [Small et al., 2004] as
224 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bwell as the presence of lobar CMBs [Poels et al., 2012; Hilal et al.,
2014].
Reduced amyloid beta-42 levels in CSF are strongly correlated
with Alzheimer’s disease, but have been associated with the APOE
e4 genotype regardless of the presence of Alzheimer’s disease
[Liu et al., 2015], and with several other brain diseases, such as
CADASIL, neuroinflammation, and Creutzfeldt-Jakob Disease
[Otto et al., 2000; Formichi et al., 2008; Krut et al., 2013]. No
studies have been published on CSF profiles in FCCM patients
[Morrison and Akers, 2003].
An intriguing question is whether the occurrence of CMBs in
this family is due to FCCM, or whether it should be attributed to a
co-existent disease such as preclinical Alzheimer’s disease or iso-
lated CAA. CMBs as such have not been reported in (F)CCM
[Morrison and Akers, 2003]. The mean prevalence of CBMs in
women aged <70 years is about 5% in the general population
[Cordonnier et al., 2007; Sveinbjornsdottir et al., 2008], therefore,
normal ageing does not seem a plausible cause in these siblings.
Based on the CSF findings, also isolated CAA is unlikely. The
aspects and location of the bleeds do not fit with other causes of
small bleeds such as vasculitis, hypertensive encephalopathy, or
coagulopathy.
Another possibility, however, is that the CMBs are in fact
small CCMs. While larger CCMs typically show signs of stag-
nant blood in the sinusoidal lumen, extravasated blood at
varying stages of degradation and a characteristic hemosiderin
rim on MRI [Al-Shahi et al., 2008], the small Zambinski’s
classification type 4 CCM lesions [Zabramski et al., 1994] are
more difficult to distinguish from CMBs. The presence of
variants in the FCCM genes in other patients with presumed
CMBs would support this hypothesis. We did not find any other
variants predicted to result in a loss of function in a cohort of
patients with multiple CBMs, however, the number of tested
individuals was small.
It is interesting to hypothesize whether ApoE and CCM2
interact. No common pathway has been described. However,
APOE e4 has been reported to increase the susceptibility to
blood-brain-barrier injury [Bell et al., 2012] and, therefore
theoretically, this genotype may result in an increased bleeding
risk of CCMs.
Taken together, the non-progressive cognitive complaints, the
lobar hypointense lesions on cerebral MRI, and the reduced
amyloid beta-42 levels in CSF may be due to the combination
of the CCM2 variant and the APOE e4 genotype, although an early
stage of Alzheimer’s disease cannot be ruled out. Unfortunately, no
other relatives were available for segregation analysis. Further
studies on CSF profiles in FCCM patients and mutations in the
FCCM genes in patients with multiple CBMs could give more
insight into the pathogenic mechanism in this family.DISCLOSURES
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